Home » Business News » 2013 » May » May 13, 2013

Galapagos to Present Three Posters on GLPG0634 at EULAR

May 13, 2013 - Mechelen, Belgium

Galapagos NV (EURONEXT BRUSSELS: GLPG)announced today that the Company will present three posters on selectiveJAK1 inhibitor GLPG0634 at the EULAR Annual European Congress ofRheumatology, which will take place from 12-15 June 2013 in Madrid, Spain.The abstracts are now available online at Informationgoing beyond that contained in the abstracts is under embargo until00:01h of the opening day of the EULAR Congress, Wednesday 12 June.

About candidate drug GLPG0634

GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitorwith selectivity for JAK1 developed by Galapagos. JAKs are criticalcomponents of signalling mechanisms utilized by a number of cytokinesand growth factors, including those that are elevated in rheumatoidarthritis patients. JAK inhibitors have shown long-term efficacy inrheumatoid arthritis studies with an early onset of action. GLPG0634differentiates from other JAK inhibitors in development by specificallytargeting JAK1, a strategy which could result in a better efficacy andsafety profile. GLPG0634 is a fully proprietary program. Uponsuccessful completion of the Phase 2b studies in RA, AbbVie will licensethe program and will assume sole responsibility for Phase 3 clinicaldevelopment and global manufacturing.

About Galapagos

Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is specialized innovel modes-of-action, with a large pipeline of four clinical, sevenpre-clinical, and 30 discovery small-molecule and antibody programsin cystic fibrosis, inflammation, antibiotics, metabolic disease, andother indications. GLPG0634 is an orally-available, selective inhibitorof JAK1 for the treatment of rheumatoid arthritis and potentially otherinflammatory diseases, about to enter Phase 2b studies. AbbVie andGalapagos signed a worldwide license agreement whereby AbbVie willbe responsible for further development and commercialization afterPhase 2b. Galapagos has another selective JAK1 inhibitor in Phase 2in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-licensed byGlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptorantagonist currently in a Phase 1b patient study in metastasis. GLPG0974is the first inhibitor of FFA2 to be evaluated clinically for thetreatment of IBD; this program is currently in a Proof-of-Concept Phase 2study. The Galapagos Group, including fee-for-service companies BioFocus,Argenta and Fidelta, has 800 employees and operates facilities infive countries, with global headquarters in Mechelen, Belgium. Furtherinformation at:

Galapagos forward-looking statements

This release may contain forward-looking statements, including, withoutlimitation, statements containing the words "believes," "anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could," "stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks,uncertainties and other factors which might cause the actual results,financial condition, performance or achievements of Galapagos, or industryresults, to be materially different from any historic or future results,financial conditions, performance or achievements expressed or implied bysuch forward-looking statements. Given these uncertainties, the reader isadvised not to place any undue reliance on such forward-looking statements.These forward-looking statements speak only as of the date of publicationof this document. Galapagos expressly disclaims any obligation to updateany such forward-looking statements in this document to reflect any changein its expectations with regard thereto or any change in events, conditionsor circumstances on which any such statement is based, unless required bylaw or regulation.

This announcement is distributed by Thomson Reuters on behalf of ThomsonReuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and otherapplicable laws; and

(ii) they are solely responsible for the content, accuracy and originalityof the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE



Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
Email Contact


Comment on this story